Paul Manning
Paul Manning is a prominent investor in AveXis, the biotech company responsible for developing Zolgensma, the world’s most expensive drug. His significant financial backing and involvement in the startup have raised questions about the motivations behind high drug prices and the commercialization of gene therapies.
Not in the pool (under ¢1).
Recent news mentions
Paul Manning is one of the liquidators who reported on the business assets.
All Blacks great Frank Bunce’s tyre business put into liquidation
New Zealand· 2026-03-05
Paul Manning was appointed as a liquidator of the company.
Guardians of Gold collapse: Retiree fights for missing $26k bullion barNew Zealand· 2025-12-04
Paul Manning is one of the liquidators appointed to oversee the liquidation of Andrew Hollis' company.
Guardians of Gold: Tauranga ex-councillor Andrew Hollis’ company in liquidation and receivershipNew Zealand· 2025-09-20
Paul Manning is the chief executive officer at Sensient.
Could aluminium become the packaging 'champion'?
United Kingdom· 2025-07-29
Paul Manning, CEO at Sensient, explains the process of creating natural colors from raw materials.
The Caribbean islands that give you a passport if you buy a homeUnited Kingdom· 2025-07-28
Paul Manning is the chief executive officer at Sensient, which creates natural colours for food.
World's thirst for the tea swallows global suppliesUnited Kingdom· 2025-07-26
Paul Manning is the chief executive officer at Sensient, creating natural colors from raw materials.
Tech firms look for natural food coloursUnited Kingdom· 2025-07-25Paul Manning, the company’s chief executive at Sensient Technologies Corp., discussed the supply issues related to natural dyes.
These natural food dyes could replace artificial colorants
United States· 2025-04-30
Liquidator Paul Manning told the Bay of Plenty Times the investigation into a potential claim against a previous funder related to a government funder.
Tauranga’s Te Tuinga Whānau Support Services Trust in liquidation months after closingNew Zealand· 2025-03-28
Paul Manning was a major investor in AveXis and made significant profits from the company's acquisition by Novartis.
What a $2 million per dose gene therapy reveals about drug pricingUnited States· 2025-02-17
